DEC 1 2010

510(k) Summary

K102587

This summary of 510(k) safety and effectiveness information is being submitted in accordance with requirements of 21 CFR Part 807.92.

Date: <u>August 30th, 2010</u>

1. Company and Correspondent making the submission:

Name - Samsung Mobile Display Co., Ltd.

Address - San #24, Nongseo-Dong, Giheung-Gu, Yongin-Si,

Gyeonggi-Do, Korea, 446-711

Telephone - +82-18-323-4075

Fax - +82-31-209-4881

Contact - Mr. Kyung Hun Yoon / Senior Manager

Internet - http://www.SAMSUNG.com

2. Device:

Trade/proprietary name

: LLX240AB01

Common Name

: Digital Flat Panel X-Ray Detector

Classification Name

: Solid State X-ray Imaging Device

3. Predicate Device:

Manufacturer

: Canon Inc.

Device

: CXDI-50G

510(k) Number

: K031447 (Decision Date - Mar. 26. 2003)

4. Classifications Names & Citations:

21CFR 892.1650, MQB, Solid State X-ray Imaging Device, Class2

5. Description:

5.1 General

LLX240AB01 is a portable digital X-ray flat panel detector that can generate images of any part of the body. This X-ray imaging system consists of a scintillator directly coupled to an a-SI TFT sensor. It makes high-resolution, high-sensitive digital images. LLX240AB01 is

designed specifically to be integrated with an operating PC and a X-Ray generator to digitalize x-ray images into RAW files. The RAW files can be made to DICOM compatible image files for a radiographic diagnosis and analysis by console SW.

5.2 Product features

LLX240AB01 is a X-Ray image acquisition device that is based on flat-panel. This device should be integrated with an operating PC and a X-Ray generator. It can be utilized for digitalizing x-ray images by converting X-ray photons into visible light and then to electronic image data that a computer can read and display for diagnostic purposes.

6. Indication for use:

LLX240AB01 Digital Flat Panel X-Ray Detector is indicated for digital imaging solution designed for providing general radiographic diagnosis of human anatomy targeting both adult and children. It is intended to replace film based radiographic diagnostic systems and provide a case diagnosis and treatment planning for physicians and other health care professionals. Not to be used for mammography.

7. Comparison with predicate device:

Samsung Mobile Display Co., Ltd., believes that LLX240AB01 is substantially equivalent to CXDI-50G of Canon Inc..

8. Safety, EMC and Performance Data:

Electrical, mechanical, environmental safety and performance testing according to standard EN/IEC 60601-1 was performed, and EMC testing was conducted in accordance with standard EN/IEC 60601-1-2(2001). All test results were satisfactory.

9. Conclusions:

In accordance with the Federal Food, Drug and Cosmetic Act, 21 CFR Part 807 and based on the information provided in this premarket notification Samsung Mobile Display Co., Ltd. concludes that LLX240AB01 is safe and effective and substantially equivalent to the predicate device as described herein.

10. Samsung Mobile Display Co., Ltd. will update and include in this summary any other information deemed seasonably necessary by FDA.



Public Health Service

Food and Drug Administration 10903 New Hampshire Avenue Document Control Room – WO66-G609 Silver Spring, MD 20993-0002

Samsung Mobile Display Co., Ltd. % Mr. Dave Kim Medical Device Regulatory Consultant VATECH America 333 Meadowlands Parkway, #303 SECAUCUS NJ 07094

AUG 2 3 2013

Re: K102587

Trade/Device Name: Digital Flat Panel X-Ray Detector/LLX240AB01

Regulation Number: 21 CFR 892.1680 Regulation Name: Stationary x-ray system

Regulatory Class: II Product Code: MQB Dated: August 30, 2010 Received: September 9, 2010

Dear Mr. Kim:

This letter corrects our substantially equivalent letter of December 1, 2010.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of

medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of *In Vitro* Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely Yours,

Janine M. Morri Acting Director

Division of Radiological Devices Office of In Vitro Diagnostic Device

Evaluation and Safety

Center for Devices and Radiological Health

Enclosure

Indications for Use

510(K) Number (if known):		DE,	C1 2010
Device Name: Digital Flat Pane	I X-Ray Detect	or /LLX240AB01	·
Indications for Use:			•
LLX240AB01 digital flat panel X-Ray detector is indicated for digital imaging solution designed for providing general radiographic diagnosis of human anatomy targeting both adult and children. It is intended to replace film based radiographic diagnostic systems and provide a case diagnosis and treatment planning for physicians and other health care professionals. Not to be used for mammography.			
Prescription Use(Part 21 CFR 801 Subpart D)	AND/OR	Over-The-Counter Us (Part 21 CFR 80	
(PLEASE DO NOT WRITE B IF NEEDED)	ELOW THIS L	INE-CONTINUE ON A	ANOTHER PAGE
Concurrence of (CDRH, Office of	of Device Evaluation(OI	DE)
		•	Page 1 of 1

(Division Sign-Off)

Division of Radiological Devices

Office of In Vitro Diagnostic Device Evaluation and Safety

... K1025